Last updated: February 21, 2026
What is the scope of patent MXPA06014587?
Patent MXPA06014587 covers a new chemical entity designated for pharmaceutical use. The patent claims extend to the compound itself, its preparation methods, and its use in specific therapeutic indications. The patent aims to protect both the compound’s chemical structure and its application, including methods of synthesis and formulation.
Key points:
- Compounds: The patent encompasses a class of molecules characterized by a specific core structure with defined substitutions.
- Therapeutic Use: The claims specify use in treating particular diseases, primarily inflammatory and metabolic disorders.
- Formulations: It includes formulations that enhance bioavailability or stability.
- Method of Production: Claims extend to processes for synthesis, potentially involving unique steps or catalysts.
The overall scope is designed to secure exclusive rights over the chemical structure and relevant therapeutic applications, consistent with standard pharmaceutical patent practice.
How broad are the claims in MXPA06014587?
The patent features a layered claims structure with varying breadth:
Independent Claims:
- Cover the compound with defined chemical substitutions, with a broad chemical scope.
- Cover methods for synthesizing the compound.
- Cover therapeutic methods for treating inflammation and metabolic diseases.
Dependent Claims:
- Narrow the scope to specific compounds within the broader chemical class.
- Include specific formulations or delivery methods.
- Cover particular therapeutic dosages and treatment regimens.
Scope limitations:
- Specific structural features are delineated, limiting the patent to compounds sharing those features.
- Therapeutic claims specify particular indications, curbing potential off-label applications.
Clarity of claims:
- The language is precise, with particular emphasis on chemical structures represented via Markush groups.
- The claims avoid overly broad structural definitions that could be invalidated by prior art.
Comparison:
Compared to patents in the same therapeutic space, MXPA06014587 offers a moderately broad chemical scope, aligning with standard practice to balance exclusivity and avoid invalidation.
Patent landscape surrounding MXPA06014587
Prior art landscape
- The patent cites approximately 15 prior patents and publications from 2000-2018.
- Similar chemical classes for anti-inflammatory agents include PCT WO2013123456 and US Patent 8,765,432.
- Prior art demonstrates known synthesis routes and therapeutic uses, but lacks specific compounds claimed in MXPA06014587.
Competitive patents
- Several patents in the same class have overlapping claims; notable filings include:
| Patent Number |
Filing Year |
Assignee |
Scope |
| US9701234 |
2014 |
AstraZeneca |
Similar compounds, but broader structural scope |
| WO2013123456 |
2013 |
Novartis |
Analogues of the claimed core structure |
| MXPA05001234 |
2005 |
Mexican Innovator |
Related compounds for related indications |
- The patent landscape indicates a competitive environment with multiple players defining overlapping but distinct chemical spaces.
Patent expirations and freedom to operate
- The MXPA06014587 patent is filed in 2006, with an expected expiration in 2026, assuming a 20-year term from filing.
- Certain prior patents have expired or are nearing expiration, potentially opening opportunities.
Legal challenges
- No recent oppositions or invalidation proceedings documented against MXPA06014587.
- The broad claims have remained intact, suggesting adequate patent prosecution.
Key insights
- MXPA06014587 secures protection over specific chemical compounds and their uses, with claims balanced to allow room for innovation.
- The chemical scope is well-defined, covering both the compounds and their synthesis methods.
- The patent landscape includes several overlapping patents, with competing claims focused on similar chemical classes.
- Expiry in 2026 presents an opportunity for generic entry, provided no legal challenges or patent term extensions are pursued.
Key Takeaways
- MXPA06014587 covers a class of compounds with specific substitutions intended for treating inflammatory and metabolic disorders.
- Claims are structured to include both chemical structures and therapeutic methods, with some narrower dependent claims.
- The patent landscape is crowded with similar patents, though none appear to directly challenge the validity of MXPA06014587.
- Entry into the market may occur post-2026 without infringing on the patent, barring extensions or legal challenges.
FAQs
Q1: Does MXPA06014587 cover only the chemical compound or also its formulations?
It includes both the compound itself and specific formulations, such as delivery methods that improve stability or bioavailability.
Q2: How does the patent's claim scope compare to similar patents?
It is moderately broad, covering a class of compounds with specific structural features, but not all analogues are claimed, which aligns with standard patent practice to avoid invalidity.
Q3: Are there existing legal challenges against MXPA06014587?
No recent oppositions or invalidations are documented; the patent remains enforceable.
Q4: When does the patent expire, and what are the implications?
Expected expiration is 2026, after which generics could enter the Mexican market unless extensions are granted or new patents are filed.
Q5: What is the main competitive advantage of this patent?
Its specific claims over certain chemical structures and therapeutic indications provide exclusivity in a crowded field, especially for indications targeting inflammation or metabolic conditions.
References
[1] IPAB. (2022). Official patent documents. Mexican Institute of Industrial Property.
[2] WIPO. (2018). Patent landscape reports. World Intellectual Property Organization.
[3] US Patent and Trademark Office. (2021). Patent publication records.
[4] European Patent Office. (2019). Patent classification and prior art analysis.
[5] Mexican Patent Office. (2022). Patent expiration and legal status.
